Literature DB >> 27454674

Clinical applications of hallucinogens: A review.

Albert Garcia-Romeu1, Brennan Kersgaard1, Peter H Addy2.   

Abstract

Hallucinogens fall into several different classes, as broadly defined by pharmacological mechanism of action, and chemical structure. These include psychedelics, entactogens, dissociatives, and other atypical hallucinogens. Although these classes do not share a common primary mechanism of action, they do exhibit important similarities in their ability to occasion temporary but profound alterations of consciousness, involving acute changes in somatic, perceptual, cognitive, and affective processes. Such effects likely contribute to their recreational use. However, a growing body of evidence indicates that these drugs may have therapeutic applications beyond their potential for abuse. This review will present data on several classes of hallucinogens with a particular focus on psychedelics, entactogens, and dissociatives, for which clinical utility has been most extensively documented. Information on each class is presented in turn, tracing relevant historical insights, highlighting similarities and differences between the classes from the molecular to the behavioral level, and presenting the most up-to-date information on clinically oriented research with these substances, with important ramifications for their potential therapeutic value. (PsycINFO Database Record (c) 2016 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27454674      PMCID: PMC5001686          DOI: 10.1037/pha0000084

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  460 in total

1.  Comparison of psilocin with psilocybin, mescaline and LSD-25.

Authors:  A B WOLBACH; E J MINER; H ISBELL
Journal:  Psychopharmacologia       Date:  1962

2.  Response of cluster headache to psilocybin and LSD.

Authors:  R Andrew Sewell; John H Halpern; Harrison G Pope
Journal:  Neurology       Date:  2006-06-27       Impact factor: 9.910

Review 3.  Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens.

Authors:  D E Nichols
Journal:  J Psychoactive Drugs       Date:  1986 Oct-Dec

4.  Long lasting effects of LSD on normals.

Authors:  W McGlothlin; S Cohen; M S McGlothlin
Journal:  Arch Gen Psychiatry       Date:  1967-11

5.  Posttraumatic stress and marijuana use coping motives: the mediating role of distress tolerance.

Authors:  Carrie M Potter; Anka A Vujanovic; Erin C Marshall-Berenz; Amit Bernstein; Marcel O Bonn-Miller
Journal:  J Anxiety Disord       Date:  2010-11-17

6.  Is ecstasy an "empathogen"? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others.

Authors:  Gillinder Bedi; David Hyman; Harriet de Wit
Journal:  Biol Psychiatry       Date:  2010-10-14       Impact factor: 13.382

7.  Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale.

Authors:  R J Strassman; C R Qualls; E H Uhlenhuth; R Kellner
Journal:  Arch Gen Psychiatry       Date:  1994-02

8.  Ibogaine induces glial activation in parasagittal zones of the cerebellum.

Authors:  E O'Hearn; D B Long; M E Molliver
Journal:  Neuroreport       Date:  1993-03       Impact factor: 1.837

9.  18-Methoxycoronardine attenuates nicotine-induced dopamine release and nicotine preferences in rats.

Authors:  S D Glick; I M Maisonneuve; K E Visker; K A Fritz; U K Bandarage; M E Kuehne
Journal:  Psychopharmacology (Berl)       Date:  1998-10       Impact factor: 4.530

10.  Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans.

Authors:  R J Strassman; C R Qualls; L M Berg
Journal:  Biol Psychiatry       Date:  1996-05-01       Impact factor: 13.382

View more
  22 in total

1.  Novel psychotherapeutics - a cautiously optimistic focus on Hallucinogens.

Authors:  Alexander M Sherwood; Thomas E Prisinzano
Journal:  Expert Rev Clin Pharmacol       Date:  2017-12-17       Impact factor: 5.045

Review 2.  Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies.

Authors:  Rafael G Dos Santos; José Carlos Bouso; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2017-02-23

Review 3.  New Paradigms of Old Psychedelics in Schizophrenia.

Authors:  Danish Mahmood; Sattam K Alenezi; Md Jamir Anwar; Faizul Azam; Kamal A Qureshi; Mariusz Jaremko
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-23

4.  (2-Aminopropyl)benzo[β]thiophenes (APBTs) are novel monoamine transporter ligands that lack stimulant effects but display psychedelic-like activity in mice.

Authors:  Deborah Rudin; John D McCorvy; Grant C Glatfelter; Dino Luethi; Dániel Szöllősi; Tea Ljubišić; Pierce V Kavanagh; Geraldine Dowling; Marion Holy; Kathrin Jaentsch; Donna Walther; Simon D Brandt; Thomas Stockner; Michael H Baumann; Adam L Halberstadt; Harald H Sitte
Journal:  Neuropsychopharmacology       Date:  2021-11-08       Impact factor: 8.294

5.  DARK Classics in Chemical Neuroscience: NBOMes.

Authors:  Christian B M Poulie; Anders A Jensen; Adam L Halberstadt; Jesper L Kristensen
Journal:  ACS Chem Neurosci       Date:  2019-11-12       Impact factor: 5.780

6.  Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey.

Authors:  Joanna Kuc; Hannes Kettner; Fernando Rosas; David Erritzoe; Eline Haijen; Mendel Kaelen; David Nutt; Robin L Carhart-Harris
Journal:  Psychopharmacology (Berl)       Date:  2021-11-04       Impact factor: 4.415

7.  Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions.

Authors:  Frederick S Barrett; Hollis Robbins; David Smooke; Jenine L Brown; Roland R Griffiths
Journal:  Front Psychol       Date:  2017-07-25

Review 8.  Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives.

Authors:  Giovanni Martinotti; Rita Santacroce; Mauro Pettorruso; Chiara Montemitro; Maria Chiara Spano; Marco Lorusso; Massimo di Giannantonio; Arturo G Lerner
Journal:  Brain Sci       Date:  2018-03-16

9.  Opportunities in Novel Psychotropic Drug Design from Natural Compounds.

Authors:  Siu Wa Tang; Wayne H Tang
Journal:  Int J Neuropsychopharmacol       Date:  2019-09-01       Impact factor: 5.176

10.  Self unbound: ego dissolution in psychedelic experience.

Authors:  Chris Letheby; Philip Gerrans
Journal:  Neurosci Conscious       Date:  2017-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.